General MedicationsSUBCUTANEOUSStandard
SUPPRELIN LA
HISTRELIN ACETATE
Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SUPPRELIN LA is listed in Drugs@FDA under application 022058 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient HISTRELIN ACETATE Form and strength IMPLANT;SUBCUTANEOUS - 50MG Sponsor ENDO OPERATIONS Submission history Latest submission status date: 2025-09-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview SUPPRELIN LA is listed in Drugs@FDA under application 022058 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient HISTRELIN ACETATE Form and strength IMPLANT;SUBCUTANEOUS - 50MG Sponsor ENDO OPERATIONS Submission history Latest submission status date: 2025-09-23 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.